This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT04153409 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Lateral Pharma Pty Ltd |
| Enrollment | 21 participants |
| Design | Interventional, Randomized, Crossover, Masking: Quadruple |
| Conditions | Acute Migraine |
| Interventions | LAT8881; Placebo |
| Start | Sep 24, 2019 |
| Primary completion | Feb 15, 2020 |
| Study completion | Apr 10, 2020 |
| Results posted | Yes, in the registry |
| Registry last updated | Apr 28, 2021 |
Compounds on this site that cite this trial
What the registry says the trial is about
This is a randomised, placebo controlled, double blind, crossover proof of concept study to investigate the efficacy and safety of oral LAT8881 in acute migraine, with or without aura.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Change in Migraine Headache Pain Score From Time of Dosing (0 Minutes) | 0 minutes, 30 minutes, 60 minutes, 90 minutes, 2 hours, 4 hours, 8 hours and 24 hours post dose |
3 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
